ArticleInternational journal of technology assessment in health care2026
Cost-utility of screening with liquid cytology or p16/Ki67 dual stain in women identified in cervical cancer triage with non 16/18 HR-HPV.
Article in International journal of technology assessment in health care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo perform a cost-utility analysis of the p16/Ki67 dual stain compared to liquid cytology (LC) in the screening of women aged 25-60 years with high-risk papillomavirus (HR-HPV) non 16/18, from the perspective of the Sistema Único de Saúde (SUS) of Brazil.
methodsA Markov-coupled decision tree cost-utility analysis model was developed for the follow-up of a hypothetical cohort of 1,000 women in the age group, in health states that simulated the natural progression of cervical cancer. The time horizon was lifetime with a discount rate of 5 percent for costs and benefits. To survey the resources used for the procedures involved, the recommendations of the Brazilian Guidelines for Cervical Cancer Screening were considered. Most of the cost data were obtained from SUS administrative and public databases. Deterministic and probabilistic sensitivity analyses were carried out.
resultsScreening with p16/Ki67 outperformed LC, resulting in an incremental gain of 2.5 quality-adjusted life years (QALYs) and an incremental cost-effectiveness ratio of R$31.40/QALY (range R$12.98-62.90/QALY), well below the reference value of R$40,000/QALY.
conclusionsThe p16/Ki67 test proved to be cost-effective in screening women with non 16/18 HR-HPV. The results can help Brazilian managers plan and make decisions about incorporating technologies for triage considering the use of HPV tests in cervical cancer screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.